These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9360852)

  • 41. Costs and utilization of intraoperative cholangiography.
    Livingston EH; Miller JA; Coan B; Rege RV
    J Gastrointest Surg; 2007 Sep; 11(9):1162-7. PubMed ID: 17602271
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The annual impact of seasonal influenza in the US: measuring disease burden and costs.
    Molinari NA; Ortega-Sanchez IR; Messonnier ML; Thompson WW; Wortley PM; Weintraub E; Bridges CB
    Vaccine; 2007 Jun; 25(27):5086-96. PubMed ID: 17544181
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The cost of obesity: the US perspective.
    Wolf AM; Colditz GA
    Pharmacoeconomics; 1994; 5(Suppl 1):34-7. PubMed ID: 10147247
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Economic burden of prescription opioid misuse and abuse.
    Strassels SA
    J Manag Care Pharm; 2009 Sep; 15(7):556-62. PubMed ID: 19739878
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The economic impact and cost of visual impairment in Australia.
    Taylor HR; Pezzullo ML; Keeffe JE
    Br J Ophthalmol; 2006 Mar; 90(3):272-5. PubMed ID: 16488942
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The economics of hypertension and stroke.
    Smith GT
    Am Heart J; 1990 Mar; 119(3 Pt 2):725-7; discussion 727-8. PubMed ID: 2106766
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Medico-social consequences and direct costs of stroke in a Swedish community.
    Terént A
    Scand J Rehabil Med; 1983; 15(4):165-71. PubMed ID: 6648390
    [TBL] [Abstract][Full Text] [Related]  

  • 48. International comparison of stroke cost studies.
    Evers SM; Struijs JN; Ament AJ; van Genugten ML; Jager JH; van den Bos GA
    Stroke; 2004 May; 35(5):1209-15. PubMed ID: 15073405
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Economics of diabetes mellitus.
    Krein SL; Funnell MM; Piette JD
    Nurs Clin North Am; 2006 Dec; 41(4):499-511, v-vi. PubMed ID: 17059971
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Estimation of costs due to hospitalization for first-ever stroke patients in northern Taiwan.
    Chiu L; Hong CT; Shyu WC; Chang TP
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 May; 62(5):261-7. PubMed ID: 10389280
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The economic impact of sight loss and blindness in the UK adult population.
    Pezzullo L; Streatfeild J; Simkiss P; Shickle D
    BMC Health Serv Res; 2018 Jan; 18(1):63. PubMed ID: 29382329
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Costs of autism spectrum disorders in the United Kingdom and the United States.
    Buescher AV; Cidav Z; Knapp M; Mandell DS
    JAMA Pediatr; 2014 Aug; 168(8):721-8. PubMed ID: 24911948
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hospital charges for stroke patients.
    Alberts MJ; Bennett CA; Rutledge VR
    Stroke; 1996 Oct; 27(10):1825-8. PubMed ID: 8841339
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Estimating the Societal Benefits of THA After Accounting for Work Status and Productivity: A Markov Model Approach.
    Koenig L; Zhang Q; Austin MS; Demiralp B; Fehring TK; Feng C; Mather RC; Nguyen JT; Saavoss A; Springer BD; Yates AJ
    Clin Orthop Relat Res; 2016 Dec; 474(12):2645-2654. PubMed ID: 27699631
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost estimates of brain disorders in Belgium.
    Schoenen J; Gianni F; Schretlen L; Sobocki P
    Acta Neurol Belg; 2006 Dec; 106(4):208-14. PubMed ID: 17323838
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Atherosclerotic cardiovascular diseases in Belgium: a cost-of-illness analysis.
    Vlayen J; De Backer G; Peers J; Moldenaers I; Debruyne H; Simoens S
    Cardiovasc Drugs Ther; 2008 Dec; 22(6):487-94. PubMed ID: 18792772
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost considerations in the pharmacological prevention and treatment of stroke.
    Alexandrov AV; Smurawska LT; Bartle W; Oh P
    Pharmacoeconomics; 1997 May; 11(5):408-18. PubMed ID: 10168030
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Stroke rehabilitation. Outcome studies and guidelines for alternative levels of care.
    Feigenson JS
    Stroke; 1981; 12(3):372-5. PubMed ID: 7245306
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The value of stroke prevention and treatment.
    Matchar DB
    Neurology; 1998 Sep; 51(3 Suppl 3):S31-5. PubMed ID: 9744830
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The economic burden of stroke care in England, Wales and Northern Ireland: Using a national stroke register to estimate and report patient-level health economic outcomes in stroke.
    Xu XM; Vestesson E; Paley L; Desikan A; Wonderling D; Hoffman A; Wolfe CD; Rudd AG; Bray BD
    Eur Stroke J; 2018 Mar; 3(1):82-91. PubMed ID: 29900412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.